Gilead Sciences: U.S. Military Veteran Battles Lymphoma With Car T-Cell Therapy: Marcus' Story

Marcus arrived home to Mississippi from his military assignment overseas, excited to see his 20-month-old son, when he realized something was wrong

"I started noticing that I had a little growth right here on my neck. About two weeks later, I had a growth in my left groin area, the size of a softball," recalls Marcus. "I was like, this isn't right. I'm 36 years old, and I had never been sick in my life."

It was cancer - a type of blood cancer known as diffuse large B-cell lymphoma.

After receiving his diagnosis, Marcus was driven to beat it. "There's no way I'm going to let this disease get the best of me and not be here to raise my son and see him grow up."

But his journey wasn't easy. After six rounds of chemotherapy, Marcus' cancer went into remission, but it was short-lived. Marcus noticed a numbing sensation on the side of his face. His lymphoma had relapsed and returned as a tumor on his trigeminal nerve.

"The second time it hit me a lot harder. I wasn't expecting it to come back," says Marcus.

His doctor at Walter Reed National Military Medical Center referred him to an hematologist-oncologist at University of Maryland Greenebaum Comprehensive Cancer Center, where he received CAR T-cell therapy.

"He had a very aggressive presentation of lymphoma. Being able to offer CAR T-cell therapy was a welcome opportunity for him," says Dr. Aaron Rapoport, the cancer center's Director of Transplant and Cellular Therapy.

The first PET CT scan showed a dramatic response to the treatment.

"I'm forever grateful," says Marcus. "I spend every moment that I can with my son because life is precious. Tomorrow is not promised. I have one son. He's going to get all of me."

View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.

Contact Info:
Spokesperson: Gilead Sciences
Website: https://www.gilead.com/
Email: info@3blmedia.com

SOURCE: Gilead Sciences



View source version on accesswire.com:
https://www.accesswire.com/730906/Gilead-Sciences-US-Military-Veteran-Battles-Lymphoma-With-Car-T-Cell-Therapy-Marcus-Story

News Provided by ACCESSWIRE via QuoteMedia

GILD
The Conversation (0)
CHMP Adopts Positive Opinion Recommending Hepcludex®  for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus

CHMP Adopts Positive Opinion Recommending Hepcludex® for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus

-- If Granted by the European Commission, Hepcludex will Become the Only Approved Treatment for HDV in the EU -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive... Keep Reading...
Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts

Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts

The recent national conversation on hepatitis C (HCV) is an encouraging step towards viral hepatitis elimination in the U.S. With its long history of leadership in viral hepatitis, Gilead continues to support efforts that focus on HCV elimination. Gilead is proud that its medicines have treated... Keep Reading...
Gilead Sciences Announces First Quarter 2023 Financial Results

Gilead Sciences Announces First Quarter 2023 Financial Results

Product Sales Excluding Veklury Increased 15% Year-Over-Year to $5.7 billion Biktarvy Sales Increased 24% Year-Over-Year to $2.7 billion Oncology Sales Increased 59% Year-Over-Year to $670 million Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first... Keep Reading...
Gilead Sciences Releases Inaugural ESG Impact Report

Gilead Sciences Releases Inaugural ESG Impact Report

Gilead Sciences recently released its inaugural Environmental, Social and Governance (ESG) Impact Report. This is an evolution of our traditional Year in Review, and uses the ESG framework to highlight the successes and achievements of the prior yearThough the report itself is new, our... Keep Reading...
abigail echo-hawk

CORRECTION: Contakt World Becomes Data Partner for Health Equity Tracker Project to Improve the Collection of De-Identified Racial & Ethnic Minority Data Using Smart Health RM, Engagency, and Future Services

Enables Contakt World mission to improve health equity and reduce disparities in the fight against Covid-19 and all diseases via award-winning SaaS platformThis document corrects and updates the final paragraph in the body of this news release. No other changes were required in this... Keep Reading...

Latest Press Releases

Related News